Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChak Sing Lauen_US
dc.contributor.authorFaith Chiaen_US
dc.contributor.authorLeonila Dansen_US
dc.contributor.authorAndrew Harrisonen_US
dc.contributor.authorTsu Yi Hsiehen_US
dc.contributor.authorRahul Jainen_US
dc.contributor.authorSeung Min Jungen_US
dc.contributor.authorMitsumasa Kishimotoen_US
dc.contributor.authorAshok Kumaren_US
dc.contributor.authorKhai Pang Leongen_US
dc.contributor.authorZhanguo Lien_US
dc.contributor.authorJuan Javier Lichaucoen_US
dc.contributor.authorWorawit Louthrenooen_US
dc.contributor.authorShue Fen Luoen_US
dc.contributor.authorRong Muen_US
dc.contributor.authorPeter Nashen_US
dc.contributor.authorChin Teck Ngen_US
dc.contributor.authorBagus Suryanaen_US
dc.contributor.authorLinda Kurniaty Wijayaen_US
dc.contributor.authorSwan Sim Yeapen_US
dc.description.abstract© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd Aim: To update recommendations based on current best evidence concerning the treatment of rheumatoid arthritis (RA), focusing particularly on the role of targeted therapies, to inform clinicians on new developments that will impact their current practice. Materials and methods: A search of relevant literature from 2014 to 2016 concerning targeted therapies in RA was conducted. The RA Update Working Group evaluated the evidence and proposed updated recommendations using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach, to describe the quality of evidence and strength of recommendations. Recommendations were finalized through consensus using the Delphi technique. Results: This update provides 16 RA treatment recommendations based on current best evidence and expert clinical opinion. Recommendations 1-3 deal with the use of conventional synthetic disease-modifying antirheumatic drugs. The next three recommendations (4-6) cover the need for screening and management of infections and comorbid conditions prior to starting targeted therapy, while the following seven recommendations focus on use of these agents. We address choice of targeted therapy, switch, tapering and discontinuation. The last three recommendations elaborate on targeted therapy for RA in special situations such as pregnancy, cancer, and major surgery. Conclusion: Rheumatoid arthritis remains a significant health problem in the Asia-Pacific region. Patients with RA can benefit from the availability of effective targeted therapies, and these updated recommendations provide clinicians with guidance on their use.en_US
dc.title2018 update of the APLAR recommendations for treatment of rheumatoid arthritisen_US
article.title.sourcetitleInternational Journal of Rheumatic Diseasesen_US University of Hong Kongen_US Tock Seng Hospitalen_US of the Philippines Manilaen_US of Otagoen_US General Hospital-Taichung Taiwanen_US Arthritis Centreen_US University College of Medicineen_US Luke's International Hospital Tokyoen_US Healthcare Ltd.en_US Universityen_US Luke's Medical Center Quezon Cityen_US Mai Universityen_US Gung Memorial Hospitalen_US of Queenslanden_US General Hospitalen_US Medical School Singaporeen_US Universityen_US Asih Ciputat Hospitalen_US Jaya Medical Centreen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.